DepoCyt: profile and news

Enzon reports substantial loss Feb 28, 2006
Enzon said that it now sees its four leading products--- Abelcet, Adagen, Depocyt and Oncaspar -- having combined 2006 revenues of greater than $100 million, vs ... - MarketWatch

Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ADAGEN(R),DEPOCYT(R), and ... - Finanzen.net,

Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ADAGEN(R), DEPOCYT(R), and ONCASPAR(R) in North America. In ... - PharmaLive.com (press release),

Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
...segmentfor 2006. This segment is currently comprised of its four marketedproducts, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ... - Finanzen.net,

Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
...segment for 2006. This segment is currently comprised of its four marketed products, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ... - Genetic Engineering News,

SkyePharma Issues EGM Notice and Recommends Shareholders to Vote ... Feb 17, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire (press release),

SkyePharma sinks as board defies rebels Feb 2, 2006
...a three-month strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur ... - Times Online,

SkyePharma defies rebels by appointing Karabelas to chair Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent,

SkyePharma Announces Appointment of New Chairman and Outcome of ... Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt® for a complication of cancer and Depodur® for the ... - Yahoo! News (press release)

SkyePharma Announces Appointment of New Chairman and Outcome of ... Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire (press release),

Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 9, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... - dBusinessNews Newark (press release),

Enzon and Micromet End Research Collaboration Nov 28, 2005
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... - Business Wire (press release),

Enzon and Micromet End Research Collaboration Nov 28, 2005
...totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and DEPOCYT(R) in ... - Finanzen.net,

Enzon and Micromet End Research Collaboration Nov 28, 2005
...threatening diseases. Enzon's specialized sales force markets ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT® in North America. In ... - Biotech Intelligence (press release),

Doxil Clinically Beneficial in Kaposi's Sarcoma Nov 8, 2005
In addition to Doxil, the committee will review Genzyme’s Campath, Pfizer’s Celebrex, SkyePharma’s DepoCyt, MedImmune’s Ethyol, Wyeth’s Mylotarg and ... - RxPG NEWS,

Oncologic Committee To Meet Nov. 8 On Accelerated Approval ... Oct 7, 2005
...review the status of Phase IV commitments for Johnson & Johnson/Alza’s Doxil, MedImmune’s Ethyol, Seragen’s Ontak, SkyePharma’s DepoCyt, Pfizer’s ... - FDA Advisory Committee

SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) Announces Interim ... Sep 28, 2005
In the first half of 2005, reported sales of all forms of Xatral(R) were Sales of DepoCyt(R) in the USA by our partner Enzon were $3.3 million, up 45% on the ... - PR Newswire (press release),

Enzon to Present at UBS Warburg Global Life Sciences Conference Sep 26, 2005
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... - Business Wire (press release),

Enzon to Present at UBS Warburg Global Life Sciences Conference Sep 26, 2005
...totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and DEPOCYT(R) in ... - Finanzen.net,

StayinFront to Provide Enzon Pharmaceuticals with Integrated CRM ... Sep 12, 2005
...or acquired a number of marketed products, including PEG-INTRON®, marketed by Schering-Plough, and ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT®, marketed in ... - Yahoo! News (press release)

StayinFront to Provide Enzon Pharmaceuticals with Integrated CRM ... Sep 12, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - PharmaLive.com (press release),

Company Information Center Sep 1, 2005
...$12.1 million in combined sales of ONCASPAR, ADAGEN, and DEPOCYT, as compared to $10.2 million in combined sales for the fourth quarter of FY 2004. ... - Business Wire (press release),

Enzon Names Dr. Ivan Horak Chief Scientific Officer Sep 6, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - Business Wire (press release),

Tanox Names Linda Paradiso Vice President of Clinical Operations ... Aug 15, 2005
She has contributed directly to the worldwide development and lifecycle management of Viracept(R), Penetrex(R), Omnicef(R), Doxil(R), DepoCyt(R), Kepivance(TM ... - PR Newswire (press release),

Enzon Announces New Executive Share Ownership Guidelines Jul 27, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - RedNova.com <**results**>

Enzon Names Craig Tooman Chief Financial Officer Jun 14, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - dBusinessNews Newark (press release),

FDA Accused of Dropping the Ball on Post-Marketing Studies of Fast ... Jun 1, 2005
He lists 16 drugs that are awaiting confirmatory post-marketing studies: Alimta, Arimidex, Celebrex, Depocyt, Ethyol, Gleevec, Iressa, Luveris, Mylotarg ... - MedPage Today,

Enzon Revises ABELCET Guidance for Fiscal 2005 Apr 20, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - dBusinessNews Newark

SkyePharma in $80m anaesthetic deal Apr 21, 2005
The latter is already SkyePharma's European marketing partner for its cancer treatment DepoCyt (cytarabine liposome injection). ... - Drug Researcher.com

SkyePharma PLC: $80 Million European Development and Marketing ... Apr 19, 2005
For example in DepoCyt(R)/DepoCyte(R) the circulating half-life of the drug cytarabine is increased from 3.4 hours to 141 hours. ... - PR Newswire

SkyePharma PLC: $80 Million European Development and Marketing ... Apr 19, 2005
...days. For example in DepoCyt®/DepoCyte® the circulating half-life of the drug cytarabine is increased from 3.4 hours to 141 hours. ... - Yahoo News

Enzon Announces Termination of Agreements with INEX Mar 17, 2005
...acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed ... - Business Wire (press release),

Other information

Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Pharmacology
Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

Mechanism Of Action
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.

Drug Category
Immunosuppressive Agents; Antivirals; Antimetabolites; Antineoplastic Agents; ATC:L01BC01

Brand Names/Synonyms
1beta-Arabinofuranasylcytosine; AR3; Ac-1075; Alexan; Ara-C; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine; Cytarabine [USAN:BAN:INN:JAN]; Cytarabinoside; Cytarabinum [INN-Latin]; Cytarbel; Cytosar; Cytosar-U; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; beta-Arabinosylcytosine; beta-Cytosine arabinoside; beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosylcytosine; 1-(beta-D-Arabinofuranosyl)cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinosylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; Cytarabine (JP14/USP); Cytarabine(USAN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine, 1-beta-D-arabinosyl-; Cytosine, 1-beta-D-arabinosyl-; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Depocyt (TN); Depocyt (liposomal); beta-D-Arabinosylcytosine

Dosage Forms
injectable solution

Absorption
less than 20% of the orally administered dose is absorbed from the gastrointestinal tract

Interactions
Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine. Steady state plasma digitoxin concentrations did not appear to change. Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. The utilization of digitoxin for such patients may be considered as an alternative. Also flucytosine.

Chemical IUPAC Name
4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

Chemical Formula
C9H13N3O5

Half Life
10 minutes

Drug Type
Approved Drug

# Accession No
APRD00499

CAS Registry Number
147-94-4